ABIVAX Société Anonyme's Obefazimod shows robust efficacy and differentiation in early Phase 3 trials. Click here to read why ...
The UK life sciences raised £1.23 billion ($1.65 billion) in venture capital investment in the first half of 2025, putting it on course to at least match the 2024 total for the full year. That's the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback